{"disease":{"id":"pediatric-low-grade-gliomas","name":"pediatric low grade gliomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03761121","title":"Developing Fast Pediatric Imaging","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Boston Children's Hospital","has_results":false},{"nct_id":"NCT07004075","title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":102,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT01734512","title":"PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"University of California, San Francisco","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}